Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 9/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5066598 | 1.00 | FDPS (0.43) | FDPSGGPS1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL2857141 | 1.00 | FDPS (0.43) | FDPSGGPS1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL16074821 | 0.97 | FDPS (0.45) | FDPSGGPS1LMNAALDH1A1HSD17B10 | |
| SCHEMBL12491942 | 0.97 | FDPS (0.45) | FDPSGGPS1LMNAALDH1A1HSD17B10 | |
| SCHEMBL16074785 | 0.97 | FDPS (0.45) | FDPSGGPS1LMNAALDH1A1HSD17B10 | |
| SCHEMBL16074826 | 0.97 | FDPS (0.45) | FDPSGGPS1LMNAALDH1A1HSD17B10 | |
| SCHEMBL9130408 | 0.97 | FDPS (0.45) | FDPSGGPS1LMNAALDH1A1HSD17B10 | |
| SCHEMBL12491913 | 0.97 | FDPS (0.45) | FDPSGGPS1LMNAALDH1A1HSD17B10 | |
| SCHEMBL9130650 | 0.97 | FDPS (0.45) | FDPSGGPS1LMNAALDH1A1HSD17B10 | |
| SCHEMBL16074775 | 0.97 | FDPS (0.45) | FDPSGGPS1LMNAALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020163295-A1 | CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF IN ASYMMETRIC OXIDATION REACTIONS | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-08-13 | — | — | WO | disclosed |
| EP-1756271-B1 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM 2,2-DISUBSTITUTED EPOXIDES | CSIR (ZA) | 2015-12-09 | — | — | EP | disclosed |
| US-20130210704-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20080286832-A1 | Methods for Obtaining Optically Active Epoxides and Vicinal Diols From 2,2-Disubstituted Epoxides | COUNCIL FOR SCIENTIFIC AND INDUSTRIAL RESEARCH (ZA) | 2008-11-20 | — | — | US | disclosed |
| EP-1756271-A2 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM 2,2-DISUBSTITUTED EPOXIDES | CSIR (ZA) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005100587-A2 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM 2,2-DISUBSTITUTED EPOXIDES | CSIR (ZA) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210704-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | FDPS 2679/4885GGPS1 3958/4885SMN1; SMN2 649/4885 |
| US-20080286832-A1 | Methods for Obtaining Optically Active Epoxides and Vicinal Diols From 2,2-Disubstituted Epoxides | EPHX2, ERG28, DERA | FDPS 220/4885GGPS1 78/4885SMN1; SMN2 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.